Increased prevalence rate of metabolic syndrome is an independent predictor of cardiovascular disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis
Objective We investigated the prevalence of metabolic syndrome (MetS) in all or nonobese patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and compared it with age- and gender-matched controls. Also, we assessed the effect of variables at diagnosis on the risk of cardiovascular disease (CVD) in all or nonobese AAV patients. Methods In this study, 173 AAV patients and 344 controls were included and MetS was defined by the National Cholesterol Education Program Adults Treatment Panel III criteria. The obesity based on body mass index (BMI) was defined as BMI ≥ 25 kg/$ m^{2} $. The follow-up duration was defined as the period from diagnosis to the last visit or to each poor outcome occurrence. Results The median age of AAV patients was 58.7 years and 57 patients were men. The prevalence of MetS was 50.9% in all AAV patients and 46.5% in nonobese AAV patients, which were significantly higher than 37.8% in all controls and 28.2% in nonobese controls. In Kaplan–Meier survival analysis, Mets at diagnosis significantly reduced the cumulative CVD-free survival rate in both all and nonobese AAV patients. In the multivariable Cox hazards model analysis, CVD during follow-up was significantly associated with both Birmingham vasculitis activity score (BVAS) (HR 1.159) and MetS at diagnosis (HR 9.036) in nonobese AAV patients. Conclusions The prevalence of MetS at diagnosis in all or nonobese AAV patients was significantly higher than those in all or nonobese controls. Furthermore, both BVAS and MetS at diagnosis increased the risk of CVD in nonobese AAV patients..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Rheumatology international - 42(2021), 2 vom: 04. Juni, Seite 291-302 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Soo Bin [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Anti-neutrophil cytoplasmic antibody |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s00296-021-04908-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2077914548 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2077914548 | ||
| 003 | DE-627 | ||
| 005 | 20230508110626.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-021-04908-1 |2 doi | |
| 035 | |a (DE-627)OLC2077914548 | ||
| 035 | |a (DE-He213)s00296-021-04908-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Lee, Soo Bin |e verfasserin |0 (orcid)0000-0001-9964-7944 |4 aut | |
| 245 | 1 | 0 | |a Increased prevalence rate of metabolic syndrome is an independent predictor of cardiovascular disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
| 520 | |a Objective We investigated the prevalence of metabolic syndrome (MetS) in all or nonobese patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and compared it with age- and gender-matched controls. Also, we assessed the effect of variables at diagnosis on the risk of cardiovascular disease (CVD) in all or nonobese AAV patients. Methods In this study, 173 AAV patients and 344 controls were included and MetS was defined by the National Cholesterol Education Program Adults Treatment Panel III criteria. The obesity based on body mass index (BMI) was defined as BMI ≥ 25 kg/$ m^{2} $. The follow-up duration was defined as the period from diagnosis to the last visit or to each poor outcome occurrence. Results The median age of AAV patients was 58.7 years and 57 patients were men. The prevalence of MetS was 50.9% in all AAV patients and 46.5% in nonobese AAV patients, which were significantly higher than 37.8% in all controls and 28.2% in nonobese controls. In Kaplan–Meier survival analysis, Mets at diagnosis significantly reduced the cumulative CVD-free survival rate in both all and nonobese AAV patients. In the multivariable Cox hazards model analysis, CVD during follow-up was significantly associated with both Birmingham vasculitis activity score (BVAS) (HR 1.159) and MetS at diagnosis (HR 9.036) in nonobese AAV patients. Conclusions The prevalence of MetS at diagnosis in all or nonobese AAV patients was significantly higher than those in all or nonobese controls. Furthermore, both BVAS and MetS at diagnosis increased the risk of CVD in nonobese AAV patients. | ||
| 650 | 4 | |a Metabolic syndrome | |
| 650 | 4 | |a Anti-neutrophil cytoplasmic antibody | |
| 650 | 4 | |a Vasculitis | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a Risk | |
| 700 | 1 | |a Kwon, Hyeok Chan |0 (orcid)0000-0003-0641-5613 |4 aut | |
| 700 | 1 | |a Kang, Mi Il |4 aut | |
| 700 | 1 | |a Park, Yong-Beom |0 (orcid)0000-0003-4695-8620 |4 aut | |
| 700 | 1 | |a Park, Jun Yong |4 aut | |
| 700 | 1 | |a Lee, Sang-Won |0 (orcid)0000-0002-8038-3341 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Springer Berlin Heidelberg, 1981 |g 42(2021), 2 vom: 04. Juni, Seite 291-302 |w (DE-627)129098183 |w (DE-600)8286-7 |w (DE-576)014434903 |x 0172-8172 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2021 |g number:2 |g day:04 |g month:06 |g pages:291-302 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00296-021-04908-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2021 |e 2 |b 04 |c 06 |h 291-302 | ||